Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS – Get Rating) was the recipient of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 5,200 shares, a growth of 73.3% from the April 30th total of 3,000 shares. Based on an average daily trading volume, of 12,900 shares, the short-interest ratio is currently 0.4 days.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of Ayala Pharmaceuticals in a research report on Saturday, May 20th. They issued a “sell” rating on the stock.
Ayala Pharmaceuticals Stock Performance
Shares of Ayala Pharmaceuticals stock opened at $0.99 on Friday. Ayala Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $7.20. The company has a market capitalization of $1.80 million, a P/E ratio of -0.11 and a beta of 2.45. The company’s fifty day moving average is $0.99 and its two-hundred day moving average is $1.31.
About Ayala Pharmaceuticals
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
- Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (ADXS)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.